Summary of risk management plan for Cervarix (Human Papillomavirus 
Vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed))  
This is a summary of the risk management plan (RMP) for Cervarix. The RMP details 
important risks of Cervarix, how these risks can be minimised, and how more information will 
(cid:24)(cid:27)(cid:1)(cid:37)(cid:24)(cid:41)(cid:23)(cid:31)(cid:36)(cid:27)(cid:26)(cid:1)(cid:23)(cid:24)(cid:37)(cid:42)(cid:41)(cid:1)(cid:14)(cid:27)(cid:39)(cid:43)(cid:23)(cid:39)(cid:31)(cid:45)(cid:51)(cid:40)(cid:1)(cid:39)(cid:31)(cid:40)(cid:33)(cid:40)(cid:1)(cid:23)(cid:36)(cid:26)(cid:1)(cid:42)(cid:36)(cid:25)(cid:27)(cid:39)(cid:41)(cid:23)(cid:31)(cid:36)(cid:41)(cid:31)(cid:27)(cid:40)(cid:1)(cid:2)(cid:35)(cid:31)(cid:40)(cid:40)(cid:31)(cid:36)(cid:29)(cid:1)(cid:31)(cid:36)(cid:28)(cid:37)(cid:39)(cid:35)(cid:23)(cid:41)(cid:31)(cid:37)(cid:36)(cid:3)(cid:5) 
Cervarix's summary of product characteristics (SmPC) and its package leaflet give essential 
information to healthcare professionals and patients on how Cervarix should be used. 
This summary of the RMP for Cervarix should be read in the context of all this information 
including the assessment report of the evaluation and its plain-language summary, all which is 
part of the European Public Assessment Report (EPAR). 
Important new concerns or changes to the current ones will be included in updates of Cervarix's 
RMP. 
I. 
The medicine and what it is used for
Cervarix is authorised for use from the age of 9 years for the prevention of premalignant ano-
genital (cervical, vulvar-vaginal and anal) lesions and cervical and anal cancers causally related 
to certain oncogenic Human Papillomavirus (HPV) types (see SmPC for the full indication). It 
contains Human Papillomavirus Vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 
as the active substance and it is given by intramuscular injection. 
Further information about the (cid:27)(cid:43)(cid:23)(cid:34)(cid:42)(cid:23)(cid:41)(cid:31)(cid:37)(cid:36)(cid:1)(cid:37)(cid:28)(cid:1)(cid:14)(cid:27)(cid:39)(cid:43)(cid:23)(cid:39)(cid:31)(cid:45)(cid:51)(cid:40)(cid:1)(cid:24)(cid:27)(cid:36)(cid:27)(cid:28)(cid:31)(cid:41)(cid:40)(cid:1)(cid:25)(cid:23)(cid:36)(cid:1)(cid:24)(cid:27)(cid:1)(cid:28)(cid:37)(cid:42)(cid:36)(cid:26)(cid:1)(cid:31)(cid:36)(cid:1)(cid:14)(cid:27)(cid:39)(cid:43)(cid:23)(cid:39)(cid:31)(cid:45)(cid:51)(cid:40)(cid:1) 
EPAR, including in its plain-language summary, available on the EMA website, under the 
(cid:35)(cid:27)(cid:26)(cid:31)(cid:25)(cid:31)(cid:36)(cid:27)(cid:51)(cid:40)(cid:1)(cid:44)(cid:27)(cid:24)(cid:38)(cid:23)(cid:29)(cid:27): 
(ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_0 
00694.jsp&mid=WC0b01ac058001d124 is the (cid:34)(cid:31)(cid:36)(cid:33)(cid:1)(cid:41)(cid:37)(cid:1)(cid:38)(cid:39)(cid:37)(cid:26)(cid:42)(cid:25)(cid:41)(cid:51)(cid:40)(cid:1)(cid:15)(cid:17)(cid:13)(cid:18)(cid:1)(cid:40)(cid:42)(cid:35)(cid:35)(cid:23)(cid:39)(cid:46)(cid:1)(cid:34)(cid:23)(cid:36)(cid:26)(cid:31)(cid:36)(cid:29)(cid:1)(cid:38)(cid:23)(cid:29)(cid:27)(cid:1) 
on the EMA webpage). 
Risks associated with the medicine and activities to minimise or 
II. 
further characterise the risks
Important risks of Cervarix, together with measures to minimise such risks and the proposed 
studies for learning more about Cervarix's risks, are outlined below. 
Measures to minimise the risks identified for medicinal products can be: 
Specific information, such as warnings, precautions, and advice on correct use, in the package 
leaflet and SmPC addressed to patients and healthcare professionals; 
(cid:16)(cid:35)(cid:38)(cid:37)(cid:39)(cid:41)(cid:23)(cid:36)(cid:41)(cid:1)(cid:23)(cid:26)(cid:43)(cid:31)(cid:25)(cid:27)(cid:1)(cid:37)(cid:36)(cid:1)(cid:41)(cid:30)(cid:27)(cid:1)(cid:35)(cid:27)(cid:26)(cid:31)(cid:25)(cid:31)(cid:36)(cid:27)(cid:51)(cid:40) packaging; 
The authorised pack size (cid:49) the amount of medicine in a pack is chosen so to ensure that the 
medicine is used correctly; 
(cid:20)(cid:30)(cid:27)(cid:1)(cid:35)(cid:27)(cid:26)(cid:31)(cid:25)(cid:31)(cid:36)(cid:27)(cid:51)(cid:40)(cid:1)(cid:34)(cid:27)(cid:29)(cid:23)(cid:34)(cid:1)(cid:40)(cid:41)(cid:23)(cid:41)(cid:42)(cid:40)(cid:1)(cid:49) the way a medicine is supplied to the patient (e.g. with or 
without prescription) can help to minimise its risks. 
Together, these measures constitute routine risk minimisation measures. 
In addition to these measures, information about adverse reactions is collected continuously 
and regularly analysed, including PSUR assessment, so that immediate action can be taken as 
necessary. These measures constitute routine pharmacovigilance activities. 
If important information that may affect the safe use of Cervarix is not yet available, it is 
listed (cid:42)(cid:36)(cid:26)(cid:27)(cid:39)(cid:1)(cid:50)(cid:35)(cid:31)(cid:40)(cid:40)(cid:31)(cid:36)(cid:29)(cid:1)(cid:31)(cid:36)(cid:28)(cid:37)(cid:39)(cid:35)(cid:23)(cid:41)(cid:31)(cid:37)(cid:36)(cid:51)(cid:1)(cid:24)(cid:27)(cid:34)(cid:37)(cid:44)(cid:5) 
II.A
List of important risks and missing information  
Important risks of Cervarix are risks that need special risk management activities to further 
investigate or minimise the risk, so that the medicinal product can be safely administered.  
Important risks can be regarded as identified or potential. Identified risks are concerns for 
which there is sufficient proof of a link with the use of Cervarix. Potential risks are concerns 
for which an association with the use of this medicine is possible based on available data, but 
this association has not been established yet and needs further evaluation. Missing information 
refers to information on the safety of the medicinal product that is currently missing and needs 
to be collected (e.g. on the long-term use of the medicine). 
List of important risks and missing information 
Important Identified Risks 
Important Potential Risks 
Missing information 
None 
None 
None 
II.B
Summary of important risks. 
The safety information in the proposed Product Information is aligned to the reference 
medicinal product. 
II.C
II.C.1
Post-authorisation development plan  
Studies which are conditions of the marketing authorisation 
There are no studies which are conditions of the marketing authorisation or specific obligation 
of Cervarix 
II.C.2 
Other studies in post-authorisation development plan 
There are no studies required for Cervarix.  
